- $549.14m
- $374.33m
- $65.44m
- 47
- 20
- 33
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.87 | ||
| Price to Tang. Book | 2.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.69% | ||
| Return on Equity | -34.95% | ||
| Operating Margin | -60.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 25.92 | 45.23 | 65.44 | 83.72 | 108.43 | 58.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 29th, 2014
- Public Since
- October 11th, 2024
- No. of Employees
- 281
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 35,868,339
- Address
- 360 N. PASTORIA AVENUE, SUNNYVALE, 94085
- Web
- https://ceribell.com/
- Phone
- +1 3026587581
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CBLL
Q1 2025 CeriBell Inc Earnings Call
Similar to CBLL
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Ceribell share price?
As of Today at 19:51 UTC, shares in Ceribell are trading at $15.31. This share price information is delayed by 15 minutes.
How has the Ceribell share price performed this year?
Shares in Ceribell last closed at $15.31 and the price had moved by over the past 365 days. In terms of relative price strength the Ceribell share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Ceribell?
The overall consensus recommendation for Ceribell is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ceribell dividend yield?
Ceribell does not currently pay a dividend.
Does Ceribell pay a dividend?
Ceribell does not currently pay a dividend.
When does Ceribell next pay dividends?
Ceribell does not currently pay a dividend.
How do I buy Ceribell shares?
To buy shares in Ceribell you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ceribell?
As of the previous close price of $15.31, shares in Ceribell had a market capitalisation of $549.14m.
Where are Ceribell shares listed?
Here are the trading details for Ceribell:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CBLL
What kind of share is Ceribell?
Based on an overall assessment of its quality, value and momentum Ceribell is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ceribell share price forecast for 2025?
The analyst consensus target price for shares in Ceribell is $33.00. That is 115.55% above the last closing price of $15.31.
Analysts covering Ceribell currently have a consensus Earnings Per Share (EPS) forecast of -$1.63 for the next financial year.
Find out moreWhat is the trend in the Ceribell share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ceribell. Over the past six months, its share price has underperformed the S&P500 Index by -38.6%.
As of the last closing price of $15.31, shares in Ceribell were trading -34.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ceribell PE Ratio?
The Ceribell PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ceribell?
We do not have data on Ceribell's directors